Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

AZ has struggled to extend the label of Imfinzi beyond that in NSCLC, other than a 2022 approval for the drug in combination with its CTLA4 inhibitor Imjudo (tremelimumab) for patients with ...

The Imfinzi approval covers the use of the drug in combination with chemo pre-surgery and on its own after surgery in NSCLC patients with a high risk of recurrence whose tumours don't express EGFR ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...